Callan Capital LLC Has $1.65 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Callan Capital LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 169.6% during the fourth quarter, HoldingsChannel reports. The firm owned 2,828 shares of the company’s stock after acquiring an additional 1,779 shares during the quarter. Callan Capital LLC’s holdings in Eli Lilly and Company were worth $1,648,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Vanguard Group Inc. grew its position in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares in the last quarter. Morgan Stanley increased its holdings in shares of Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after acquiring an additional 83,915 shares in the last quarter. Northern Trust Corp boosted its position in Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after buying an additional 355,317 shares during the last quarter. International Assets Investment Management LLC boosted its position in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Eli Lilly and Company by 2.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock worth $2,382,339,000 after purchasing an additional 88,016 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Morgan Stanley upped their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Truist Financial restated a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday, April 15th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Up 1.2 %

Shares of LLY traded up $8.64 during midday trading on Friday, reaching $733.51. 2,009,249 shares of the stock were exchanged, compared to its average volume of 2,265,427. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. The firm has a 50 day simple moving average of $761.79 and a 200-day simple moving average of $666.06. Eli Lilly and Company has a 12-month low of $380.77 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.09 earnings per share. Research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.